Curcumin COVID-19 studies. Studies typically use advanced formulations for greatly improved bioavailability.
Recent:Sadeghizadeh Hegde Teshima Shojaei.
Submit updates/corrections .
Jun 3 |
(Preprint) (meta analysis) | Curcumin for COVID-19: real-time meta analysis of 24 studies |
| Statistically significant improvements are seen for mortality, hospitalization, progression, recovery, and viral clearance. 16 studies from 14 independent teams in 6 different countries show statistically significant improvements in iso.. | ||
Apr 29 |
et al., Phytotherapy Research, doi:10.1002/ptr.7844 | Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized |
| 92% lower progression [p=0.02], 25% shorter hospitalization [p=0.007], and 68% improved recovery [p<0.0001]. RCT 42 hospitalized moderate/severe COVID-19 patients in Iran, showing lower progression and improved recovery with nano-curcumin. Nano-curcumin 70mg bid for 14 days. | ||
Apr 13 |
et al., Research Square, doi:10.21203/rs.3.rs-2780614/v1 (Preprint) (In Vitro) | Potential Mechanism of Curcumin and Resveratrol against SARS-CoV-2 |
| In Vitro study showing that curcumin and resveratrol can inhibit SARS-CoV-2 3CLpro activity and spike protein-mediated cell entry, cytokine storm, and oxidative stress. Combined treatment was more effective than either treatment alone. | ||
Mar 28 |
et al., Natural Product Research, doi:10.1080/14786419.2023.2194647 (In Vitro) | Antiviral activity of curcumin and its analogs selected by an artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells |
| In Vitro study of curcumin and its analogs with 6 of 8 compounds showing SARS-CoV-2 antiviral activity with EC50 values <30μM and binding inhibitory activity with IC20 values <30μM. | ||
Mar 13 |
et al., ACS Omega, doi:10.1021/acsomega.2c07326 (Review) | Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far? |
| Review of clinical studies on curcumin formulations for improved bioavailability. Authors note that bioavailability has been improved by a factor of >50,000. | ||
Feb 17 |
et al., Phytotherapy Research, doi:10.1002/ptr.7778 (meta analysis) | The effectiveness of nano‐curcumin on patients with |
| Meta analysis of 8 nano-curcumin COVID-19 studies, showing significantly lower mortality and shorter hospitalization with treatment. | ||
Jan 18 |
et al., Archives of Clinical and Medical Case Reports, 7:1 | The Efficacy of a Plant Based Formulation in the Symptomatic Management of Mild COVID-19 Cases: A Double Blind, Randomized Controlled Trial |
| 98% improved recovery [p<0.0001] and 76% improved viral clearance [p<0.0001]. RCT 50 patients in India testing NAOQ19 which includes curcumin along with many other ingredients, showing improved recovery and viral clearance. SOC included vitamin C and zinc. NAOQ19 is a plant based formulation with 19 ingredients fro.. | ||
Jan 18 |
et al., Frontiers in Nutrition, doi:10.3389/fnut.2022.1023997 | The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19—Results from a pragmatic randomized clinical trial |
| 29% improved recovery [p=0.11] and 91% improved viral clearance [p=0.05]. Small RCT with 50 outpatients, 25 treated with curcumin, quercetin, and vitamin D, showing improved recovery and viral clearance with treatment. 168mg curcumin, 260mg, 360IU vitamin D3 daily for 14 days. | ||
Jan 14 |
et al., Phytotherapy Research, doi:10.1002/ptr.7724 | Curcumin for the treatment of COVID-19 patients: A meta-analysis of randomized controlled trials |
| 62% lower mortality [p=0.003]. Meta analysis of 13 curcumin RCTs showing lower mortality with treatment. Authors note that subgroup analysis suggested improved efficacy with early treatment and with combined treatment. | ||
Nov 23 |
et al., Phytotherapy Research, doi:10.1002/ptr.7683 | Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers |
| 11% faster recovery [p=0.04]. RCT 208 moderate COVID-19 patients in India, 103 treated with a combination of turmeric, ashwagandha, boswellia, and ginger, showing improved recovery with treatment. The dose of curcumin is unknown and bioavailability may be poor. | ||
Sep 17 |
et al., European Journal of Pharmacology, doi:10.1016/j.ejphar.2022.175267 | Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function |
| 71% lower mortality [p=0.15] and 86% improved recovery [p=0.04]. RCT with 30 nanocurcumin and 30 control patients in Iran, showing lower mortality and improved recovery, without statistical significance, and improved NK cell function. 160mg nanocurcumin for 21 days. | ||
Jun 10 |
et al., F1000Research, doi:10.12688/f1000research.121933.1 | Effect of natural products use prior to infection with COVID-19 on disease severity and hospitalization: A self-reported cross-sectional survey study |
| 31% lower hospitalization [p=0.08] and 13% lower severe cases [p=0.47]. Survey 2,148 COVID-19 recovered patients in Jordan, showing lower hospitalization with turmeric prophylaxis, not reaching statistical significance. | ||
Jun 6 |
et al., Trials, doi:10.1186/s13063-022-06375-w | The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial |
| Small RCT 46 outpatients in Iran, 23 treated with curcimin-piperine, showing no significant differences in recovery. 1000mg curcumin and 10mg piperine/day for 14 days. | ||
May 19 |
et al., Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.17337 | Effect of ArtemiC in patients with COVID-19: A Phase II prospective study |
| 77% improved recovery [p=0.04], 92% lower need for oxygen therapy [p=0.01], 13% shorter hospitalization [p=0.92], and 10% improved viral clearance [p=0.77]. RCT 50 hospitalized patients in Israel, 33 treated with curcumin, vitamin C, artemisinin, and frankincense oral spray, showing improved recovery with treatment. | ||
May 1 |
et al., Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552 | Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study |
| In Silico study showing showing significant inhibitory potential of curcumin for omicron. | ||
May 1 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.898062 | Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19—Results From a Pilot Open-Label, Randomized Controlled Trial |
| 33% improved recovery [p=0.15] and 50% improved viral clearance [p=0.009]. RCT 50 COVID+ outpatients in Pakistan, 25 treated with curcumin, quercetin, and vitamin D, showing significantly faster viral clearance, significantly improved CRP, and faster resolution of acute symptoms (p=0.154). 168mg curcumin, 260mg .. | ||
Apr 28 |
et al., Phytotherapy Research, doi:10.1002/ptr.7468 | The effect of curcumin on the risk of mortality in patients with COVID-19: A systematic review and meta-analysis of randomized trials |
| 77% lower mortality [p=0.002]. Meta analysis of 3 curcumin RCTs showing lower mortality with treatment. Author notes the small sample sizes of the included trials. | ||
Apr 9 |
et al., Phytotherapy Research, doi:10.1002/ptr.7463 (In Vitro) | In vitro antiviral activity against SARS-CoV-2 of common herbal medicinal extracts and their bioactive compounds |
| In Vitro study showing antiviral activity of curcumin longa, with protection against SARS-CoV-2-induced cytopathic effects at a concentration of 3.125μg/ml. | ||
Mar 25 |
et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2022.102824 | A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
| 86% lower mortality [p=0.24], 86% lower ventilation [p=0.24], 10% shorter hospitalization [p=0.4], and 32% faster recovery [p=0.001]. RCT with 60 hospitalized patients treated with Ayurcov and 60 control patients in India, showing improved viral clearance and faster symptom resolution in the mild/moderate group, but no significant differences in the severe group. Ayurco.. | ||
Mar 22 |
et al., COVID, doi:10.3390/covid2040031 | A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating Concentrated Phytochemical-Rich Nutritional Capsule in Addition to a Probiotic Capsule on Clinical Outcomes among Individuals with COVID-19—The UK Phyto-V Study |
| 44% greater improvement [p=0.02]. RCT 147 long COVID patients in the UK, 56 treated with a phytochemical-rich concentrated food capsule, showing improved recovery with treatment. Treatment included curcumin, bioflavonoids, chamomile, ellagic acid, and resveratrol. | ||
Feb 28 |
et al., Tropical Journal of Pharmaceutical Research, doi:10.4314/tjpr.v21i2.13 | Immune-boosting effect of natural remedies and supplements on progress of, and recovery from COVID-19 infection |
| 42% lower severe cases [p=0.55]. Retrospective survey-based analysis of 349 COVID-19 patients, showing a lower risk of severe cases with vitamin D, zinc, turmeric, and honey prophylaxis in unadjusted analysis, without statistical significance. REC/UG/2020/03. | ||
Feb 22 |
et al., Pharmacognosy Journal, doi:10.5530/pj.2022.14.27 | The Effect of Curcumin and Virgin Coconut Oil Towards Cytokines Levels in COVID-19 Patients at Universitas Sebelas Maret Hospital, Surakarta, Indonesia |
| 53% improved viral clearance [p<0.0001]. RCT with 30 patients treated with curcumin and virgin coconut oil (VCO), and 30 SOC patients in Indonesia, showing faster viral clearance with treatment. Treatment also reduced IL-1β, IL-2, IL-6, IL-18, and IFN-β levels. VCO improves the.. | ||
Feb 4 |
et al., International Journal of Molecular Sciences, doi:10.3390/ijms23031771 | Molecular Docking and Molecular Dynamics Simulations Discover Curcumin Analogue as a Plausible Dual Inhibitor for SARS-CoV-2 |
| In Silico molecular dynamics simulation study finding a curcumin analogue (curA) as a promising dual inhibitor for SARS-CoV-2. | ||
Jan 28 |
et al., ICE on IMERI, 2021 (Preprint) | Curcumin as adjuvant Therapy in Mild - Moderate Covid 19 |
| 41% shorter hospitalization [p=0.05]. Retrospective 246 hospitalized patients in Indonesia, 136 treated with curcumin, showing shorter hospitalization time with treatment. All patients received vitamin C, D, and zinc. | ||
Jan 21 |
et al., European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022 (In Vitro) | Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants |
| In Vitro study testing combinations of plant extracts and micronutrients with several variants of SARS-CoV-2. A combination of vitamin C, N-acetylcysteine, curcumin, quercetin, resveratrol, theaflavin, naringenin, baicalin, and broccoli e.. | ||
Jan 17 |
et al., Phytotherapy Research, doi:10.1002/ptr.7375 | Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial |
| 26% lower mortality [p=0.74], 50% lower progression [p=0.47], and 45% improved recovery [p=0.09]. RCT 60 hospitalized patients in Iran, 30 treated with nano-curcumin, showing significant improvements in inflammatory cytokines, and improvements in clinical outcomes without statistical significance. 240 mg/day nano-curcumin for 7 days. | ||
Jan 12 |
et al., Phytotherapy Research, doi:10.1002/ptr.7374 | Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial |
| 29% shorter hospitalization [p=0.22] and 9% improved recovery. RCT 48 hospitalized patients in Iran, 24 treated with nanocurcumin, showing lower hospitalization time with treatment. The number of patients shown in Table 3 (31 and 27 for each arm) is inconsistent with the number reported as randomized.. | ||
Jan 7 |
et al., Nutrients, doi:10.3390/nu14020256 | Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials |
| Review of 6 COVID-19 curcumin studies showing that treatment resulted in significant improvement in symptoms, duration of hospitalization, and mortality, and a significant decrease in proinflammatory cytokines and increase in anti-inflamm.. | ||
Dec 27 2021 |
et al., Research Square, doi:10.21203/rs.3.rs-1165680/v1 (Preprint) | An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial |
| 89% improved recovery [p=0.05] and 24% improved viral clearance [p=0.47]. Small RCT with 39 patients treated with NOQ19 and 37 placebo patients, showing improved recovery, without statistical significance. NOQ19 has multiple ingredients including curcumin and antiandrogen glycyrrhiza glabra. CTRI/2021/05/033790. | ||
Nov 16 2021 |
et al., Molecules, doi:10.3390/molecules26226900 (In Vitro) | Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms |
| In Vitro study showing antiviral and anti-inflammatory effects of curcumin during SARS-CoV-2 infection. Inhibition was seen with Vero E6 cells pre-infection and post-infection, and with D614G and the delta variant. The anti-inflammatory e.. | ||
Nov 14 2021 |
et al., Food Chemistry, doi:10.1016/j.foodchem.2021.131594 (In Vitro) | Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols |
| In Silico and In Vitro study of plant polyphenols identifying quercetin, curcumin, ellagic acid, epigallocatechin gallate and resveratrol as SARS-CoV-2 3CLpro inhibitors with IC50 between 11.8µM and 23.4µM. Real-time binding was analyzed.. | ||
Oct 22 2021 |
et al., Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104965 | Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach |
| In Silico study showing strong binding affinity of curcumin and diacetylcurcumin with SARS-CoV-2 RNA-dependent RNA polymerase. Comparison with remdesivir and favipiravir suggested greater potential of these compounds as an RdRp inhibitor. | ||
Oct 11 2021 |
et al., Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2021/8447545 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive) for COVID-19 Patients |
| 43% improved recovery [p=0.004] and 6% faster viral clearance [p=0.47]. RCT 100 patients in India, 50 treated with ImmuActive (curcumin, andrographolides, resveratrol, zinc, selenium, and piperine), showing improved recovery with treatment. | ||
Sep 23 2021 |
et al., Viruses, doi:10.3390/v13101914 (In Vitro) | Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro |
| In Vitro study showing curcumin neutralizes SARS-CoV2 in vitro with low subtoxic concentrations. Authors note that the clinical use of curcumin is hindered by poor bioavailability, and recommend using methods to increase bioavailability s.. | ||
Sep 19 2021 |
et al., Phytotherapy Research, doi:10.1002/ptr.7294 | A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients |
| 46% worse recovery [p=0.9]. Small RCT with 40 low risk patients in Iran, 20 treated with nano-curcumin, showing no significant difference in outcomes with treatment. Authors note that treatment can improve peripheral blood inflammatory indices and modulate immune re.. | ||
Sep 8 2021 |
et al., Cureus, doi:10.7759/cureus.17829 | Turmeric as a Possible Treatment for COVID-19-Induced Anosmia and Ageusia |
| Small case study of 2 patients, showing significant improvement in taste and smell shortly after one dose of a turmeric supplement. Authors note that the risk of one dose is low in healthy individuals not on medications metabolized by cyt.. | ||
Aug 10 2021 |
et al., Journal of Ayurveda and Integrated Medical Sciences, doi:10.21760/jaims.6.4.6 | A prospective, multi center, single blind, randomized controlled study evaluating “AyurCoro3” as an adjuvant in the treatment of mild to moderate COVID |
| 89% lower mortality [p=0.12], 75% lower ventilation [p=0.37], 46% improved recovery [p=0.002], and 10% shorter hospitalization [p=0.4]. RCT 174 patients in India, 87 treated with AyurCoro-3 (turmeric, gomutra, potassium alum, khadisakhar, bos indicus milk, ghee), showing faster recovery with treatment. EC/NEW/INST/2019/245. | ||
Jul 9 2021 |
et al., Medicine, doi:10.1097/MD.0000000000026601 | The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation |
| Bioavailability RCT comparing CURCUGEN, a 50% curcuminoids-concentrated turmeric extract, with curcuminoids 95% standardized extract (C-95), showing significant improvements in bioavailability. | ||
Jun 29 2021 |
et al., Foods, doi:10.3390/foods10071503 (In Vitro) | Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity |
| In Vitro study of several plant extracts, showing strong inhibition of SARS-CoV-2 3CLpro activity by turmeric rhizomes. Commercial curcumin also inhibited 3CLpro activity, but did not fully account for the inhibitory effect of turmeric rh.. | ||
Jun 19 2021 |
et al., Food Science and Nutrition, doi:10.1002/fsn3.2226 | Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial |
| 86% lower hospitalization [p=0.24] and 21% faster recovery [p=0.37]. RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower hospitalization and faster recovery with treatment. | ||
Jun 17 2021 |
et al., PLOS ONE, doi:10.1371/journal.pone.0253489 (In Vitro) | Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions |
| In Vitro study of 56 polyphenols showing that curcumin has high binding affinity to the RBD of the SARS-CoV-2 spike protein, inhibits ACE2 at non-toxic concentrations, and decreases activity of TMPRSS2. Promising results were also seen fo.. | ||
Jun 15 2021 |
et al., Pathogens, doi:10.3390/pathogens10060758 (In Vitro) | Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2 |
| Vero E6 In Vitro study showing curcumin, hesperidin, and quercetin significantly inhibited SARS-CoV-2 replication, and In Silico analysis with promising Mpro and spike docking results. | ||
May 28 2021 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362 | Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial |
| 82% lower mortality [p=0.02]. RCT 140 patients, 70 treated with curcumin and piperine (for absorption), and 70 treated with probiotics, showing faster recovery, lower progression, and lower mortality with curcumin. | ||
May 11 2021 |
et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18105086 | Patients’ Behavior Regarding Dietary or Herbal Supplements before and during COVID-19 in Saudi Arabia |
| 31% lower hospitalization [p=0.1]. Retrospective survey-based analysis of 738 COVID-19 patients in Saudi Arabia, showing lower hospitalization with vitamin C, turmeric, zinc, and nigella sativa, and higher hospitalization with vitamin D. For vitamin D, most patients contin.. | ||
May 7 2021 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.675287 (Review) | Curcumin as a Potential Treatment for COVID-19 |
| Review of curcumin for COVID-19 including potential antiviral, anti-inflammatory, anticoagulant, antiplatelet, and cytoprotective effects. | ||
Mar 28 2021 |
et al., Life Sciences, doi:10.1016/j.lfs.2021.119437 | Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2 |
| 83% lower mortality [p=0.11]. RCT 40 hospitalized, 40 ICU, and 40 control patients in Iran, showing lower mortality and improved regulatory T cell responses with nanocurcumin treatment (SinaCurcumin). | ||
Jan 3 2021 |
et al., Phytotherapy Research, doi:10.1002/ptr.7004 | Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial |
| 94% lower progression [p=0.001], 38% improved recovery [p=0.04], and 45% shorter hospitalization [p=0.001]. Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1. | ||
Nov 16 2020 |
et al., Journal of Clinical Trials, S3:004 | A Randomized, Comparative Clinical Study to Evaluate the Activity of CurvicTM Formulation for Management of SARS-COV-2 Infection (COVID-19) |
| 33% improved 7-point scale results [p=0.0001]. RCT 200 COVID-19 positive patients in India, 100 treated with Curcumin, Vitamin C, Vitamin K2-7, and L-Selenomethionine, showing faster recovery with treatment. | ||
Nov 13 2020 |
et al., Metabolism Open, doi:10.1016/j.metop.2020.100066 (Review) | The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19 |
| Review of the potential benefits of bromelain and curcumin for COVID-19, and potential synergistic effects of the combination. | ||
Oct 20 2020 |
et al., Int. Immunopharmacol., doi:10.1016/j.intimp.2020.107088 | Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients |
| 50% lower mortality [p=0.3]. Small RCT with 40 nano-curcumin patients and 40 control patients showing lower mortality with treatment. Authors conclude that nano-curcumin may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mR.. | ||
Jun 7 2020 |
et al., MDPI AG, doi:10.20944/preprints202005.0439.v3 (Preprint) | Comparative Docking Studies on Curcumin with COVID-19 Proteins |
| In Silico study showing high binding affinity for the SARS-CoV-2 nucleocapsid and nsp10 proteins with curcumin. Authors propose curcumin for COVID-19 drug development. | ||
Jun 4 2020 |
, P., Cell Stress and Chaperones, doi:10.1007/s12192-020-01126-9 (Theory) | COVID-19 and heme oxygenase: novel insight into the disease and potential therapies |
| Proposal that COVID-19 risk is related to low intracellular heme oxygenase (HO-1), and that therapies that raise HO-1 may be beneficial, which includes fluvoxamine, certain anesthetics (sevoflurane or isoflurane), hemin, estrogen, statins.. | ||
Apr 24 2020 |
et al., ChemRxiv, doi:10.26434/chemrxiv.12181404.v1 (Preprint) | In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2 |
| In Silico study of natural compounds identifying quercetin, curcumin, hispidulin, cirsimaritin, sulfasalazine, and artemisin as potential compounds that inhibit SARS-CoV-2. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.